PIKTOR’s PI3K/AKT/mTOR endometrial cancer data and 2026 catalysts. Read the latest analysis on the stock here.
Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing PIKTOR, an investigational all-oral, ...
Experts in cell signaling at the Babraham Institute have identified how prostate cancer cells achieve cell growth free from the usual growth cues and regulators. This discovery has implications for ...
The phosphatidylinositol 3-kinase (PI3K)-AKT signaling pathway is one of the most critical and extensively investigated signaling pathways. It is the central regulator of various cellular processes ...
BLU-222, an investigational, oral, potent, and highly selective CDK2 inhibitor (CDK2i), as monotherapy in patients (pts) with advanced solid tumors and in combination with ribociclib (RIBO) and ...
"Our finding that the PI3K/Akt pathway is anchored on p53 in the nucleus was entirely unexpected," says Cryns, a physician-scientist and professor at UW School of Medicine and Public Health. The ...
WNT pathway alterations in bevacizumab-treated early-onset colorectal cancer: An artificial intelligence–driven and disparity-aware precision oncology analysis. Longitudinal clinical validation of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results